がんにおける遠隔デジタル生理学的データ収集: MSK レジストリ プロトコル

Potential participants will be identified by a member of the patient's care team, a protocol investigator, or research staff at Memorial Sloan Kettering Cancer Center (MSK).

Inclusion Criteria:

Project 1: HealthKit

• Individuals who meet at least one of the following criteria:

  • Diagnosis of new onset early-stage (I-III), low-grade (I-II), or locally advanced solid tumor
  • Historical diagnosis of primary invasive solid tumor
  • Diagnosis of metastatic (stage IV) or high-grade (III-IV) disease
  • Enrolled onto an investigational trial in the EDD Service
  • Seen in the MSK UCC from 2021 and onwards
  • Completion of Survivorship Patient Self-Assessment
  • Adult without a history of cancer <50 years of age
  • Adult without a history of cancer ≥ 50 years of age

• ≥18 years old

• Own an Apple iPhone or Android with valid operating software

• Self-reported "very well" comprehension of written and verbal English language

• Willing and able to provide informed consent and HIPAA authorization for the release of personal health information

Project 2: DigIT-Ex

Individuals who meet one of the following criteria:

• Patients at MSK who are:

• Scheduled to undergo any type of BMT (Cohort 1)

• Diagnosed with new onset AML and scheduled to initiate antineoplastic therapy (Cohort 2)

• Scheduled to undergo any surgery for prostate cancer (Cohort 3)

• Scheduled to undergo any lung cancer surgery (Cohort 4)

• Scheduled to undergo TNT for locally advanced rectal cancer (Cohort 5)

• Scheduled to initiate androgen deprivation therapy for at least 12 months and has one of the following prostate cancer diagnoses (Cohort 6):

• High risk/very high localized, locally advanced,

• Biochemically recurrent prostate cancer

• Treatment naïve, low-volume metastatic prostate cancer

• Scheduled Scheduled to undergo chemotherapy for metastatic pancreatic cancer (Cohort 7)

• Receiving outpatient care at Memorial Sloan Kettering Cancer Center (MSK)(Cohort 10)

• Diagnosed with metastatic cancer to bone For purposes of this study, metastatic bone disease includes skeletal involvement from multiple myeloma (Cohort 10)

• Scheduled for non-emergent orthopaedic surgery to stabilize lower-extremity bone metastases (Cohort 10)

• Able to undergo at least 5 consecutive days of preoperative monitoring prior to surgery (Cohort 10)

• Have had a CT scan including the L3 vertebral level within 3 months before surgery (used to assess skeletal muscle mass and sarcopenia) (Cohort 10)

• Have a ≥50% predicted likelihood of 3-month postoperative survival, as estimated by the PATHFx clinical decision-support tool (Cohort 10

• Individuals without cancer <50 years of age (Cohort 8)

• Individuals without cancer ≥50 years of age (Cohort 9)

  • 18 to 90 years old at the time of consent
  • Willing and able to download the Withings Health Mate app onto their personal mobile device
  • Willing to provide mobile digital physiological data for a period of at least six months to a maximum of one year following consent for Cohorts 1-9, and 4 months following consent for Cohort 10.
  • Willing to provide informed consent

Exclusion Criteria:

Project 1: HealthKit

• Unable or unwilling to successfully export and /or share physiological data

Project 2: DigIT-Ex

• Unable or unwilling to appropriately use digital platforms or devices
• Require a wheelchair for ambulation (Cohort 10)
• Are undergoing stabilization surgery for a primary bone tumor (rather than metastatic disease) (Cohort 10)